Predict Drug Toxicity without Guesswork
Consider Organs-On-Chips, Pathway Simulations, and Transgenic Mice
Cell-Line Development Poised for Growth
For Real Gains, Try Engineering Better Cell Lines
Finding Targets in Cancer’s Metabolic Quirks
To Head Off Cancer at the Pass, Take Directions from Pathway Analysis
A Better Environment for Tissue Repair
Looking to Epigenetics and the Hydra to Facilitate Healing and Slow Aging
For full access to this article login to GEN Select now.
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
- With some medical interventions, immunogenicity is the whole point—hence the “good” immunogenicity provoked by vaccines. Immunogenicity is much to be avoided, however, when biotherapeutics are deployed. Biotherapeutics such as recombinant proteins or monoclonal antibodies (mAbs) may instigate “bad” immunogenicity, potentially nullifying any hoped-for benefits or even causing autoimmune reactions. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.